CN1289143C - 降低糖尿病患者空腹血糖和减缓体重增加的方法 - Google Patents

降低糖尿病患者空腹血糖和减缓体重增加的方法 Download PDF

Info

Publication number
CN1289143C
CN1289143C CNB02124880XA CN02124880A CN1289143C CN 1289143 C CN1289143 C CN 1289143C CN B02124880X A CNB02124880X A CN B02124880XA CN 02124880 A CN02124880 A CN 02124880A CN 1289143 C CN1289143 C CN 1289143C
Authority
CN
China
Prior art keywords
insulin
glucose
patient
imbedibility
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB02124880XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1393265A (zh
Inventor
威廉·H·兰德舒尔茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1393265A publication Critical patent/CN1393265A/zh
Application granted granted Critical
Publication of CN1289143C publication Critical patent/CN1289143C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CNB02124880XA 2001-06-21 2002-06-21 降低糖尿病患者空腹血糖和减缓体重增加的方法 Expired - Fee Related CN1289143C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30004901P 2001-06-21 2001-06-21
US60/300,049 2001-06-21

Publications (2)

Publication Number Publication Date
CN1393265A CN1393265A (zh) 2003-01-29
CN1289143C true CN1289143C (zh) 2006-12-13

Family

ID=23157477

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB02124880XA Expired - Fee Related CN1289143C (zh) 2001-06-21 2002-06-21 降低糖尿病患者空腹血糖和减缓体重增加的方法

Country Status (15)

Country Link
US (2) US20030079747A1 (cg-RX-API-DMAC10.html)
EP (1) EP1270012A1 (cg-RX-API-DMAC10.html)
JP (1) JP2003012543A (cg-RX-API-DMAC10.html)
KR (1) KR20020097033A (cg-RX-API-DMAC10.html)
CN (1) CN1289143C (cg-RX-API-DMAC10.html)
AU (1) AU4884102A (cg-RX-API-DMAC10.html)
CA (1) CA2390757A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ20022151A3 (cg-RX-API-DMAC10.html)
HK (1) HK1049617B (cg-RX-API-DMAC10.html)
HU (1) HUP0202042A3 (cg-RX-API-DMAC10.html)
IL (1) IL150209A0 (cg-RX-API-DMAC10.html)
NZ (1) NZ519403A (cg-RX-API-DMAC10.html)
PL (1) PL354641A1 (cg-RX-API-DMAC10.html)
SK (1) SK9042002A3 (cg-RX-API-DMAC10.html)
ZA (1) ZA200204859B (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054606A1 (en) * 2002-12-13 2004-07-01 Pfizer Products Inc. Method of decreasing hepatic glucose output in diabetic patients
WO2004078198A1 (en) * 2003-03-04 2004-09-16 The Technology Development Company Ltd. Long acting injectable insulin composition and methods of making and using thereof
US20070178166A1 (en) * 2005-12-15 2007-08-02 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
WO2008118387A2 (en) * 2007-03-23 2008-10-02 Wayne State University Erythrocyte atp-release modulators
EP2060268A1 (en) * 2007-11-15 2009-05-20 Novo Nordisk A/S Pharmaceutical compositions for pulmonary or nasal delivery of peptides
CA2765617A1 (en) * 2009-07-22 2011-01-27 Eli Lilly And Company Method for predicting weight gain associated with a pharmaceutical therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5230884A (en) * 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
DK10191D0 (da) * 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
ES2141108T3 (es) * 1991-07-02 2000-03-16 Inhale Inc Metodo y dispositivo para proporcionar medicamentos en aerosol.
US5320094A (en) * 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) * 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5743250A (en) * 1993-01-29 1998-04-28 Aradigm Corporation Insulin delivery enhanced by coached breathing
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
DE69535897D1 (de) * 1994-03-07 2009-01-22 Nektar Therapeutics Verfahren und Zusammensetzung für die pulmonale Darreichung von Insulin
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
ATE387925T1 (de) * 1994-09-21 2008-03-15 Nektar Therapeutics Vorrichtung und verfahren zum dispergieren von trockenen pulvermedikamenten
US5898028A (en) * 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
DE19733651A1 (de) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
CN1210058C (zh) * 1998-10-16 2005-07-13 诺沃挪第克公司 用于肺送递的稳定的浓缩胰岛素制剂
JP2002543092A (ja) * 1999-04-27 2002-12-17 イーライ・リリー・アンド・カンパニー 肺投与用インスリン結晶
AU5453300A (en) * 1999-06-29 2001-01-31 Eli Lilly And Company Insulin crystals for pulmonary administration
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
JP4590158B2 (ja) * 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法
KR20030097876A (ko) * 2001-05-21 2003-12-31 넥타르 테라퓨틱스 화학적으로 개질된 인슐린의 폐 투여

Also Published As

Publication number Publication date
CZ20022151A3 (cs) 2003-04-16
NZ519403A (en) 2005-03-24
JP2003012543A (ja) 2003-01-15
EP1270012A1 (en) 2003-01-02
US20030079747A1 (en) 2003-05-01
IL150209A0 (en) 2002-12-01
HUP0202042A3 (en) 2004-06-28
KR20020097033A (ko) 2002-12-31
CA2390757A1 (en) 2002-12-21
HU0202042D0 (cg-RX-API-DMAC10.html) 2002-08-28
CN1393265A (zh) 2003-01-29
HUP0202042A2 (hu) 2004-05-28
AU4884102A (en) 2003-01-02
HK1049617A1 (en) 2003-05-23
HK1049617B (zh) 2007-03-16
US20050220722A1 (en) 2005-10-06
PL354641A1 (en) 2002-12-30
SK9042002A3 (en) 2003-05-02
ZA200204859B (en) 2004-01-28

Similar Documents

Publication Publication Date Title
JP2548056B2 (ja) Ｉ型糖尿病に係る自己免疫疾患の抑制および予防用製剤
CN1098679C (zh) 用于胰岛素肺部给药的方法和组合物
AU2009200894B2 (en) A method of reducing serum proinsulin levels in type 2 diabetics
TWI496580B (zh) 胰島素長效調配物
CN114949183B (zh) 一种替尔泊肽粉雾剂及其制备方法
KR20010073033A (ko) 인슐리노트로픽 펩티드의 투여 방법
JP2004520345A (ja) 糖尿病を有する被験者にガストリン／ｃｃｋ受容体リガンド及びｅｇｆ受容体リガンド組成物を用いた島細胞新生治療方法の効果持続
Garnock-Jones et al. Insulin glulisine: a review of its use in the management of diabetes mellitus
CN1393265A (zh) 降低糖尿病患者空腹血糖和减缓体重增加的方法
Tibaldi Actions of insulin beyond glycemic control: a perspective on insulin detemir
AU2021237808A1 (en) AZD1656 for use in the treatment of pneumonitis and/or mycorditis caused by a coronavirus
US20020164267A1 (en) Method of preventing type 2 diabetes with aerosolized insulin
US20040112376A1 (en) Method of inducing euglycemia in diabetic patients
JPH06510753A (ja) インスリン欠乏哺乳動物治療用のインスリンおよびアミリンを含有する組成物
WO2011075611A1 (en) Compositions and methods for non-invasive treatment of chronic complication of diabetes
US20020147134A1 (en) Method of preventing and treating the complications of insulin dependent diabetes mellitus
AU2006203457A1 (en) Method of decreasing fasting sugars and weight gains in diabetic patients
Hatem A study of newly initiated antidiabetic medication in primary care in Region Uppsala: A cross-sectional study
CN118286156A (zh) 减重多肽药物组合物、鼻喷剂及其制备方法
CN110302359A (zh) 一种可降低血糖的制剂、制备方法及其应用
Page Insulin, other hypoglycemic drugs, and glucagon
AU2002253447A1 (en) Method of preventing type 2 diabetes with aerosolized insulin

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20061213